- Home
- IAUX vs TYRA Comparison
IAUX vs TYRA Comparison
Compare IAUX & TYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IAUX
- TYRA
- Stock Information
- Founded
- IAUX 2020
- TYRA 2018
- Country
- IAUX United States
- TYRA United States
- Employees
- IAUX N/A
- TYRA N/A
- Industry
- IAUX
- TYRA Biotechnology: Pharmaceutical Preparations
- Sector
- IAUX
- TYRA Health Care
- Exchange
- IAUX Nasdaq
- TYRA Nasdaq
- Market Cap
- IAUX 507.4M
- TYRA 571.9M
- IPO Year
- IAUX N/A
- TYRA 2021
- Fundamental
- Price
- IAUX $0.93
- TYRA $12.52
- Analyst Decision
- IAUX Buy
- TYRA Strong Buy
- Analyst Count
- IAUX 1
- TYRA 8
- Target Price
- IAUX $1.50
- TYRA $31.00
- AVG Volume (30 Days)
- IAUX 5.6M
- TYRA 239.1K
- Earning Date
- IAUX 11-11-2025
- TYRA 11-06-2025
- Dividend Yield
- IAUX N/A
- TYRA N/A
- EPS Growth
- IAUX N/A
- TYRA N/A
- EPS
- IAUX N/A
- TYRA N/A
- Revenue
- IAUX $76,622,000.00
- TYRA N/A
- Revenue This Year
- IAUX $79.79
- TYRA N/A
- Revenue Next Year
- IAUX $92.04
- TYRA N/A
- P/E Ratio
- IAUX N/A
- TYRA N/A
- Revenue Growth
- IAUX 40.21
- TYRA N/A
- 52 Week Low
- IAUX $0.34
- TYRA $6.42
- 52 Week High
- IAUX $1.26
- TYRA $29.60
- Technical
- Relative Strength Index (RSI)
- IAUX 75.79
- TYRA 59.07
- Support Level
- IAUX $0.85
- TYRA $11.70
- Resistance Level
- IAUX $0.90
- TYRA $12.91
- Average True Range (ATR)
- IAUX 0.04
- TYRA 0.69
- MACD
- IAUX 0.01
- TYRA -0.03
- Stochastic Oscillator
- IAUX 92.97
- TYRA 53.16
About IAUX i-80 Gold Corp.
i-80 Gold Corp is a well-financed gold and silver producer engaged in the exploration, development, and production of gold, silver, and poly-metallic deposits. The Company's principal assets include the Ruby Hill Mine, Lone Tree Mine, Granite Creek Mine, and McCoy-Cove Project.
About TYRA Tyra Biosciences Inc.
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are TYRA-300, TYRA-200, and TYRA-430: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.